Recordati announces the closing of a License and Supply Agreement with Tolmar International Ltd, to commercialise Eligard (leuprorelin acetate), in Europe, Turkey, Russia and other countries.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Camcevi, from Accord BioPharma and intended for the treatment of the cancer of the prostate in adult men when the cancer is ‘hormone-dependent’, which means that it responds to treatments that reduce the levels of the hormone testosterone.